Core Viewpoint - Jianmin Group reported a decline in both revenue and net profit for the first three quarters of 2025, indicating challenges in its business operations [1] Financial Performance - For the first three quarters of 2025, the company's operating revenue was 2.55 billion yuan, a year-on-year decrease of 11.4% [1] - The net profit attributable to shareholders was 286 million yuan, down 11.16% year-on-year [1] - The net profit excluding non-recurring items was 256 million yuan, reflecting a decline of 5.58% year-on-year [1] Quarterly Breakdown - In the third quarter, the operating revenue was 747 million yuan, showing a year-on-year decrease of 14.3% [1] - The net profit attributable to shareholders for the third quarter was 65.11 million yuan, down 20.8% year-on-year [1] - The net profit excluding non-recurring items for the third quarter was 60.22 million yuan, a decline of 21.3% year-on-year [1] Segment Analysis - From the beginning of the year to the reporting period, the company's operating revenue decreased by 11.43%, with the pharmaceutical manufacturing segment experiencing a growth of 19.67% due to increased revenue from leading and new products [1] - Conversely, the pharmaceutical commercial segment saw a significant decline in revenue by 36.91%, attributed to the company's ongoing optimization of its commercial subsidiaries' business structure and the gradual reduction of low-margin and inefficient operations [1]

Core Insights - The core viewpoint of the article highlights the financial performance of Jianmin Group for the third quarter of 2025, indicating a decline in both revenue and net profit compared to the previous year [1] Financial Performance - In Q3 2025, the company's operating revenue was 747 million yuan, a year-on-year decrease of 14.27% [1] - The net profit for Q3 2025 was 65.11 million yuan, down 20.84% year-on-year [1] - For the first three quarters of 2025, the total operating revenue reached 2.552 billion yuan, reflecting an 11.43% decline compared to the same period last year [1] - The net profit for the first three quarters was 286 million yuan, which is an 11.16% decrease year-on-year [1] - The basic earnings per share stood at 1.88 yuan [1] Segment Performance - The pharmaceutical manufacturing segment experienced a year-on-year growth of 19.67%, attributed to increased revenue from leading and new products [1] - Conversely, the pharmaceutical commercial segment saw a significant decline in revenue, down 36.91%, due to the company's ongoing optimization of its commercial subsidiaries' business structure, leading to a reduction in low-margin and inefficient operations [1]